Targeting synuclein-γ to counteract drug resistance in cancer

Expert Opinion on Therapeutic Targets

Volumn 12, Issue 1, 2008, Pages 59-68

  Singh, Vinay K ^a   Jia, Zongchao ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Adjuvant therapy; Checkpoint signaling; Drug resistance; Peptide inhibitor; Protein protein interaction

Indexed keywords

ANKYRIN; ANTINEOPLASTIC AGENT; BUB1 RELATED PROTEIN; ESTROGEN RECEPTOR ALPHA; GAMMA SYNUCLEIN; MATRIX METALLOPROTEINASE; MESSENGER RNA; PACLITAXEL; SYNTHETIC PEPTIDE;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BREAST CANCER; CANCER INCIDENCE; CANCER INHIBITION; CANCER SURVIVAL; COLON CANCER; DISEASE FREE SURVIVAL; DRUG DESIGN; DRUG TARGETING; ESOPHAGUS CANCER; GENE OVEREXPRESSION; GEOGRAPHIC DISTRIBUTION; HUMAN; LIVER CANCER; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MEDULLOBLASTOMA; METASTASIS POTENTIAL; MOLECULAR MECHANICS; NONHUMAN; OVARY CANCER; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; RETINOBLASTOMA; REVIEW; SEQUENCE ALIGNMENT; STOMACH CANCER; SURVIVAL RATE; SURVIVAL TIME; UTERINE CERVIX CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; GAMMA-SYNUCLEIN; HUMANS; NEOPLASMS; PEPTIDES;

EID: 39049158181     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.12.1.59     Document Type: Review

References (102)

1. American Cancer Society. Homepage. Available from: URL: www.cancer.org [last accessed 27 November, 2007]
2. Datamonitor. Homepage. Available from: URL: www.datamonitor.com [last accessed 27 November, 2007]
3. Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999;17(8):2341-54
4. Valero V, Jones SE, Von Hoff DD, et al. A Phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 1998;16(10):3362-8
5. Wani MC, Taylor HL, Wall ME, et al. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxua brevifolia. J Am Chem Soc 1971;93(9):2325-7
6. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277(5698):665-7
7. Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Ann Rev Med 1997;48:353-74
8. Perez RP, Hamilton TC, Ozols RF, Young RC. Mechanisms and modulation of resistance to chemotherapy in ovarian cancer. Cancer 1993;71(4 Suppl):1571-80
9. Roninson IB. Tumor senescence as a determinant of drug response in vivo. Drug Resist Updat 2002;5(5):204-8
10. Zaffaroni N, Daidone MG. Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist Update 2002;5(2):65-72
11. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990;42(3):155-99
12. Baird RD, Kaye SB. Drug resistance reversal - are we getting closer? Eur J Cancer 2003;39(17):2450-61
13. Fojo T. p53 as a therapeutic target: unresolved issues on the road to cancer therapy targeting mutant p53. Drug Resist Update 2002;5(5):209-16
14. Mollinedo F, Gajate C. Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 2003;8(5):413-50
15. Fahy BN, Schlieman M, Virudachalam S, Bold RJ. AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2. Br J Cancer 2003;89(2):391-7
16. Dong QG, Sclabas GM, Fujioka S, et al. The function of multiple IkappaB: NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. Oncogene 2002;21(42):6510-19
17. Menendez JA, Vellon L, Mehmi I, et al. A novel CYR61-triggered 'CYR61-alphavbeta3 integrin loop' regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway. Oncogene 2005;24(5):761-79
18. Hari M, Loganzo F, Annable T, et al. Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules. Mol Cancer Ther 2006;5(2):270-8
19. Han EK, Tahir SK, Cherian SP, et al. Modulation of paclitaxel resistance by annexin IV in human cancer cell lines. Br J Cancer 2000;83(1):83-8
20. Zachos G, Black EJ, Walker M, et al. Chk1 is required for spindle checkpoint function. Dev Cell 2007;12(2):247-260
21. Hille S, Rein DT, Riffelmann M, et al. Anticancer drugs induce mdr1 gene expression in recurrent ovarian cancer. Anticancer Drugs 2006;17(9):1041-4
22. McCubrey JA, Steelman LS, Abrams SL, et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 2006;46:249-79
23. Chavanpatil MD, Patil Y, Panyam J. Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux. Int J Pharm 2006;320(1-2):150-6
24. Saeki T, Tsuruo T, Sato W, Nishikawsa K. Drug resistance in chemotherapy for breast cancer. Cancer Chemother Pharmacol 2005;56(Suppl 1):84-9
25. Coley HM, Labeed FH, Thomas H, Hughes MB Biophysical characterization of MDR breast cancer cell lines reveals the cytoplasm is critical in determining drug sensitivity. Biochim Biophys Acta 2007;1770(4):601-8
26. Gottesman MM, Hrycyna CA, Schoenlein PV, et al. Genetic analysis of the multidrug transporter. Annu Rev Genet 1995;29:607-49
27. Chen CJ, Chin JE, Ueda K, et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986;47(3):381-9
28. Cole SR, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258(5088):1650-4
29. Allen JD, Schinkel AH. Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ ABCG2). Mol Cancer Ther 2002;1(6):427-34
30. Vargas-Roig LM, Gago FE, Tello O, et al. Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer 1998;79(5):468-75
31. Gupta A, Inaba S, Wong OK, et al. Breast cancer-specific gene 1 interacts with the mitotic checkpoint kinase BubR1. Oncogene 2003;22(48):7593-9
32. Singh VK, Zhou Y, Marsh JA, et al. Synuclein-gamma targeting peptide inhibitor that enhances sensitivity of breast cancer cells to antimicrotubule drugs. Cancer Res 2007;67(2):626-33
33. Zhou Y, Inaba S, Liu J. Inhibition of synuclein-gamma expression increases the sensitivity of breast cancer cells to paclitaxel treatment. Int J Oncol 200;29(1):289-95
34. George JM. The synucleins. Genome Biol 2002;3(1):REVIEWS3002
35. Lavedan C. The synuclein family. Genome Res 1998;8(9):871-80
36. Bohlen Und HO. Synucleins and their relationship to Parkinson's disease. Cell Tissue Res 2004;318(1):163-74
37. Iwai A. Properties of NACP/alpha-synuclein and its role in Alzheimer's disease. Biochim Biophys Acta 2000;1502(1):95-109
38. Duda JE, Lee VM, Trojanowski JQ. Neuropathology of synuclein aggregates. J Neurosci Res 2000;61(2):121-7
39. Ji H, Liu YE, Jia T, et al. Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing. Cancer Res 1997;57(4):759-64
40. Lavedan C, Leroy E, Dehejia A, et al. Identification, localization and characterization of the human gamma-synuclein gene. Hum Genet 1998;103(1):106-12
41. Liu J, Spence MJ, Zhang YL, et al. Transcriptional suppression of synuclein gamma (SNCG) expression in human breast cancer cells by the growth inhibitory cytokine oncostatin M. Breast Cancer Res Treat 2000;62(2):99-107
42. Lu A, Zhang F, Gupta A, Liu J. Blockade of AP1 transactivation abrogates the abnorma expression of breast cancer-specific gene 1 in breast cancer cells. J Biol Chem 2002;277(35):31364-72
43. Jiang Y, Liu YE, Goldberg ID, Shi YE. Gamma synuclein, a novel heat-shock protein-associated chaperone, stimulates ligand-dependent estrogen receptor alpha signaling and mammary tumorigenesis. Cancer Res 2004;64(13):4539-46
44. Jiang Y, Liu YE, Lu A, et al. Stimulation of estrogen receptor signaling by gamma synuclein. Cancer Res 2003;63(14):3899-903
45. Jia T, Liu YE, Liu J, Shi YE. Stimulation of breast cancer invasion and metastasis by synuclein gamma. Cancer Res 1999;59(3):742-7
46. Bruening W, Giasson BI, Klein-Szanto AJ, et al. Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary. Cancer 2000;88(9):2154-63
47. Wu K, Weng Z, Tao Q, et al. Stage-specific expression of breast cancer-specific gene gamma-synuclein. Cancer Epidemiol Biomarkers Prev 2003;12(9):920-5
48. Zhao W, Liu H, Liu W, et al. Abnormal activation of the synuclein-gamma gene in hepatocellular carcinomas by epigenetic alteration. Int J Oncol 2006;28(5):1081-8
49. Zhou CQ, Liu S, Xue LY, et al. Down-regulation of gamma-synuclein in human esophageal squamous cell carcinoma. World J Gastroenterol 2003;9(9):1900-3
50. Fung KM, Rorke LB, Giasson B, et al. Expression of alpha-, beta-, and gamma-synuclein in glial tumors and medulloblastomas. Acta Neuropathol (Berl) 2003;106(2):167-75
51. Ahmad M, Attoub S, Singh MN, et al. {Gamma}-synuclein and the progression of cancer. FASEB J 2007;21:3419-30
52. Czekierdowski A, Czekierdowska S, Wielgos M, et al. The role of CpG islands hypomethylation and abnormal expression of neuronal protein synuclein-gamma (SNCG) in ovarian cancer. Neuro Endocrinol Lett 27(3):381-6
53. Surgucheva IG, Sivak JM, Fini ME, et al. Effect of gamma-synuclein overexpression on matrix metalloproteinases in retinoblastoma Y79 cells. Arch Biochem Biophys 2003;410(1):167-76
54. Yanagawa N, Tamura G, Honda T, et al. Demethylation of the synuclein gamma gene CpG island in primary gastric cancers and gastric cancer cell lines. Clin Cancer Res 2004;10(7):2447-51
55. Iwaki H, Kageyama S, Isono T, et al. Diagnostic potential in bladder cancer of a panel of tumor markers (calreticulin, gamma-synuclein, and catechol-o-methyltransferase) identified by proteomic analysis. Cancer Sci 2004;95(12):955-61
56. Gupta A, Godwin AK, Vanderveer L, et al. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma. Cancer Res 2003;63(3):664-73
57. Liu H, Liu W, Wu Y, et al. Loss of epigenetic control of synuclein-gamma gene as a molecular indicator of metastasis in a wide range of human cancers. Cancer Res 2005;65(17):7635-43
58. Chabottaux V, Noel A. Breast cancer progression: insights into multifaceted matrix metalloproteinases. Clin Exp Metastasis 2007: published online 30 Oct 2007, doi:10.1007/s10585-007-9113-7
59. Shin HJ, Baek KH, Jean AH, et al. Dual roles of human BubR1, a mitotic checkpoint kinase, in the monitoring of chromosomal instability. Cancer Cell 2003;4(6):483-97
60. Blajeski AL, Phan VA, Kottke TJ, Kaufmann SH. G(1) and G(2) cell-cycle arrest following microtubule depolymerization in human breast cancer cells. J Clin Invest 2002;110(1):91-9
61. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4(4):253-65
62. Abal M, Andreu JM, Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets 2003;3(3):193-203
63. Cleveland DW, Mao Y, Sullivan KF. Centromeres and kinetochores: from epigenetics to mitotic checkpoint signaling. Cell 2003;112(4):407-21
64. Chi YH, Jeang KT. Aneuploidy and cancer. J Cell Biochem 2007;102(3):531-8
65. Musacchio A, Salmon ED. The spindle-assembly checkpoint in space and time. Nat Rev Mol Cell Biol 2007;8(5):379-93
66. Fu Y, Ye D, Chen H, et al. Weakened spindle checkpoint with reduced BubR1 expression in paclitaxel-resistant ovarian carcinoma cell line SKOV3-TR30. Gynecol Oncol 2007;105(1):66-73
67. Weaver BA, Cleveland DW. Decoding the links between mitosis, cancer, and chemotherapy: the mitotic checkpoint, adaptation, and cell death. Cancer Cell 2005;8(1):7-12
68. Inaba S, Li C, Shi YE, et al. Synuclein gamma inhibits the mitotic checkpoint function and promotes chromosomal instability of breast cancer cells. Breast Cancer Res Treat 2005;94(1):25-35
69. Surguchov A, Palazzo RE, Surgucheva I. Gamma synuclein: subcellular localization in neuronal and non-neuronal cells and effect on signal transduction. Cell Motil Cytoskeleton 2001;49(4):218-28
70. Anand S, Penrhyn-Lowe S, Venkitaraman AR. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 2003;3(1):51-62
71. Kienitz A, Vogel C, Morales I, et al. Partial downregulation of MAD1 causes spindle checkpoint inactivation and aneuploidy, but does not confer resistance towards taxol. Oncogene 2005;24(26):4301-10
72. Lee EA, Keutmann MK, Dowling ML, et al. Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells. Mol Cancer Ther 2004;3(6):661-9
73. Sudo T, Nitta M, Says H, Ueno NT. Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res 2004;64(7):2502-8
74. Pan ZZ, Bruening W, Giasson BI, et al. Gamma-synuclein promotes cancer cell survival and inhibits stress- and chemotherapy drug-induced apoptosis by modulating MAPK pathways. J Biol Chem 2002;277(38):35050-60
75. Lanzi C, Cassinelli G, Cuccuru G, et al. Cell cycle checkpoint efficiency and cellular response to paclitaxel in prostate cancer cells. Prostate 2001;48(4):254-64
76. Goncalves A, Braguer D, Kamath K, et al. Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics. Proc Natl Acad Sci USA 2001;98(20):11737-42
77. Gustafsson JA, Warner M. Estrogen receptor beta in the breast: role in estrogen responsiveness and development of breast cancer. J Steroid Biochem Mol Biol 2000;74(5):245-8
78. Dougherty MK, Schumaker LM, Jordan VC, et al. Estrogen receptor expression and sensitivity to paclitaxel in breast cancer. Cancer Biol Ther 2004;3(5):460-7
79. Chene P. Drugs targeting protein-protein interactions. ChemMedChem 2006;1(4):400-11
80. Arkin MR, Wells JA. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov 2004;3(4):301-17
81. Pettit FK, Bowie JU. Protein surface roughness and small molecular binding sites. J Mol Biol 1999;285(4):1377-82
82. Marsh JA, Singh VK, Jia Z, Forman-Kay JD. Comparison of secondary structure propensities calculated from chemical shifts in α- and γ-synuclein: Implications for fibrillation and the evolution of intrinsically disordered proteins. Protein Sci 2006;12:2795-804
83. Dyson HJ, Wright PE. Intrinsically unstructured proteins and their functions. Nat Rev Mol Cell Biol 2005;6(3):197-208
84. Fink AL. Natively unfolded proteins. Curr Opin Struct Biol 2005;15(1):35-41
85. Koshland DE Jr. The key-lock theory and the induced fit theory. Angew Chem Int Ed Eng 1995;33(23-24):2375-8
86. Wadia JS, Dowdy SF. Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv. Drug Deliv Rev 2005;57(4):579-96
87. Torchilin VP. Tatp-mediated intracellular delivery of pharmaceutical nanocarriers. Biochem Soc Trans 2007;35(Pt 4):816-20
88. Guo J, Shou C, Meng L, et al. Neuronal protein synuclein gamma predicts poor clinical outcome in breast cancer. Int J Cancer 2007;121(6):1296-305
89. Wu K, Quan Z, Weng Z, et al. Expression of neuronal protein synuclein gamma gene as a novel marker for breast cancer prognosis. Breast Cancer Res Treat 2007;101(3):259-67
90. Amer DA, Irvine GB, El Agnaf OM. Inhibitors of alpha-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders. Exp Brain Res 2006;173(2):223-33
91. El Agnaf OM, Paleologou KE, Greer B, et al. A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders. FASEB J 2004;18(11):1315-7
92. Bodles AM, El Agnaf OM, Greet B, et al. Inhibition of fibril formation and toxicity of a fragment of alpha-synuclein by an N-methylated peptide analogue. Neurosci Lett 2004;359(1-2):89-93
93. Foerg C, Merkle HP. On the biomedical promise of cell penetrating peptides: limits versus prospects. J Pharm Sci 2007: published online 30 Aug 2007, doi:10.1002/jps.21117
94. Dass CR, Choong PF. Carrier-mediated delivery of peptidic drugs for cancer therapy. Peptides 2006;27(11):3020-8
95. Asai T, Oku N. Liposomalized oligopeptides in cancer therapy. Methods Enzymol 2005;391:163-76
96. Schwartz JJ, Zhang S. Peptide-mediated cellular delivery. Curr Opin Mol Ther 2000;2(2):162-7
97. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998;279(5349):377-80
98. Ellerby HM, Map W, Ellerby LM, et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 1999;5(9):1032-8
99. Curnis F, Sacchi A, Borgna L, et al. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 2000;18(11):1185-90
100. Yusuf RZ, Duan Z, Lamendola DE, et al. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 2003;3(1):1-19
101. Swanton C, Tomlinson I, Downward J. Chromosomal instability, colorectal cancer and taxane resistance. Cell Cycle 2006;5(8):818-23
102. Mendoza FJ, Espino PS, Cann KL, et al. Anti-tumor chemotherapy utilizing peptide-based approaches - apoptotic pathways, kinases, and proteasome as targets. Arch Immunol Ther Exp 2005;53(1):47-60